

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2002

DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-16133
(Commission File Number)

06-1245881
(IRS Employer
Identification No.)

1100 Summer Street, Stamford, Connecticut 06905
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (203) 323-8668

N/A
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure

On December 9, 2002, Delcath Systems, Inc. (the "Company") issued a press release announcing it has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of securities in the form of units. Each unit will consist of shares of common stock and warrants to purchase shares of common stock. The Company's press release dated December 9, 2002 is incorporated herein by reference and filed as an exhibit hereto.

Item 7. Financial Statements and Exhibits

- (a) Not applicable
- (b) Not applicable
- (c) Exhibits

Exhibit No. -----	Description -----
99	Press Release dated December 9, 2002 of Delcath Systems, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

By: /s/ M. S. KOLY

M. S. Koly
President and Chief Executive
Officer

Date: December 13, 2002

EXHIBIT INDEX

Exhibit No. -----	Description -----
99	Press Release dated December 9, 2002 of Delcath Systems, Inc.

News From:

Delcath Systems, Inc.

Redington, Inc.
49 Richmondville, Westport, CT 06880

=====
Release Date: IMMEDIATE

Exhibit 99

Contact:

M.S. Koly
Chief Executive Officer
Delcath Systems, Inc.
203/323-8668
www.delcath.com

Thomas Redington
Redington, Inc
203/222-7399
212/926-1733
www.redingtoninc.com

DELGATH ANNOUNCES A PUBLIC OFFERING OF SECURITIES

STAMFORD, CT DEC 9 - Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of securities in the form of units. Each unit will consist of shares of common stock and warrants to purchase shares of common stock. Delcath anticipates that, if the offering is completed, it will use the net proceeds it receives for working capital to fund human clinical trials and pay other associated costs in connection with obtaining pre-marketing approval of the Delcath system from the U.S. Food and Drug Administration. Roan/Meyers Associates, L.P. will represent the underwriters in connection with the anticipated offering.

Delcath is a development stage company that has developed a system, the Delcath system, which is designed to administer high doses of chemotherapy to the liver for treatment of liver cancer. The Delcath system is not currently approved for marketing by the FDA, and it cannot be marketed in the United States without FDA pre-marketing approval.

The registration statement has been filed with the Securities and Exchange Commission but has not yet become effective. The units may not be sold nor may offers to buy the units be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Any statements released by Delcath that are forward-looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "expects," words of similar import and variations on such words are intended to identify forward-looking statements. Investors are cautioned that forward-looking statements necessarily involve risks and uncertainties which are difficult to predict and actual outcomes may vary materially from what is expressed or forecasted in such forward-looking statements.

When available, copies of the preliminary prospectus filed as part of the registration statement may be obtained without charge, by directing a

-more-

request to Delcath Systems, Inc., 1100 Summer Street, Stamford, Connecticut 06905, Attention: M. S. Koly.

Delcath, a development-stage company, is in the business of developing and marketing a proprietary drug delivery system capable of introducing, and removing, high-dose chemotherapy agents to a diseased organ system while greatly inhibiting their entry into the general circulatory system.

#

This release contains "FORWARD-LOOKING STATEMENTS" BASED ON CURRENT EXPECTATIONS BUT INVOLVING KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. ACTUAL RESULTS OR ACHIEVEMENTS MAY BE MATERIALLY DIFFERENT FROM THOSE EXPRESSED OR IMPLIED. DELCATH PLANS AND

OBJECTIVES ARE BASED ON ASSUMPTIONS INVOLVING JUDGMENTS WITH RESPECT TO FUTURE ECONOMIC, COMPETITIVE AND MARKET CONDITIONS, ITS ABILITY TO CONSUMMATE, AND THE TIMING OF, ACQUISITIONS AND FUTURE BUSINESS DECISIONS, ALL OF WHICH ARE DIFFICULT OR IMPOSSIBLE TO PREDICT ACCURATELY AND MANY OF WHICH ARE BEYOND ITS CONTROL. THEREFORE, THERE CAN BE NO ASSURANCE THAN ANY FORWARD-LOOKING STATEMENT WILL PROVE TO BE ACCURATE.

12/9/02